Jan Wald
Jan Wald
company education loses market money training
One thing the company loses by not being part of J&J is not having more money for market development education and training
boston company fda gain permit product quality saying scientific seemed until
What the FDA seemed to be saying is that it doesn't know if Boston Scientific has a systemic, corporate-wide quality policy, and until it does the FDA will not permit the company to gain product approvals in adulterated plants.
boston deal power reach scientific
Boston Scientific will do everything in its power to reach a deal with Guidant.
along believe boston deal matter small strategic
I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.
acquire growth investors rate
My sense is J&J is going to have to acquire to get a growth rate that investors will think is respectable.
time
But that is an awfully long time to look out for pharmaceuticals.
feeling
I have a feeling that Temecula is pretty safe.
accept board boston clearing price scientific terms
The price wasn't as important as clearing up some terms and conditions. If Boston Scientific has done that, then I don't know why Guidant's board wouldn't accept this bid.
attractive certainly definitely
I think they (St. Jude) definitely look like they are in play. They certainly would be an attractive candidate.
easily
I think they easily could go up to $76 without a lot of damage.
company hard indication processes
It is another indication that the processes could have been better ? but the company is working hard on it already.
actions company eventually expenses given remain stay
I think there are some actions the company will have to take and some expenses the company will have to incur that will make it tough. I still think given those parameters, it can be, stay and remain an independent company and eventually flourish.
hard people work
People are Guidant's most important asset, ... so there are hard trade-offs for Guidant to work through.
growth jude needs people thinking walk
J&J needs something like Guidant to revitalize its growth. People are now thinking that if J&J does walk away, St. Jude is in their scopes.